586 related articles for article (PubMed ID: 22158731)
1. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
2. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
3. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
[TBL] [Abstract][Full Text] [Related]
4. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
5. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
[TBL] [Abstract][Full Text] [Related]
6. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
7. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
Garvey WT; Ryan DH; Henry R; Bohannon NJ; Toplak H; Schwiers M; Troupin B; Day WW
Diabetes Care; 2014 Apr; 37(4):912-21. PubMed ID: 24103901
[TBL] [Abstract][Full Text] [Related]
8. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
9. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
Hsia DS; Gosselin NH; Williams J; Farhat N; Marier JF; Shih W; Peterson C; Siegel R
Diabetes Obes Metab; 2020 Apr; 22(4):480-491. PubMed ID: 31696603
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Winslow DH; Bowden CH; DiDonato KP; McCullough PA
Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
[TBL] [Abstract][Full Text] [Related]
13. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
14. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
16. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
17. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
[TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Guo F; Garvey WT
Diabetes Care; 2017 Jul; 40(7):856-862. PubMed ID: 28455281
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
